Literature DB >> 12671341

Metolazone and its role in edema management.

Domenic A Sica1.   

Abstract

Metolazone is commonly administered in conjunction with a loop diuretic to manage volume overload in patients otherwise resistant to loop diuretic therapy alone. Metolazone is a thiazide-type diuretic that is characterized by slow and sometimes erratic absorption when administered as the Zaroxylyn product. This absorptive profile together with the large volume of distribution and high degree of renal clearance for metolazone provide the pharmacologic basis for a favorable diuretic combination effect. Zaroxylyn should always be administered cautiously and only with a means of surveillance allowing the patient's weight to be carefully monitored so as to avoid excessive diuresis. If an excessive diuresis occurs with a metolazone and loop diuretic combination both drugs should be stopped temporarily. The temptation should be avoided to simply reduce the doses of either metolazone or the loop diuretic as a means to controlling an active diuresis. Copyright 2003 CHF, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12671341     DOI: 10.1111/j.1527-5299.2003.01907.x

Source DB:  PubMed          Journal:  Congest Heart Fail        ISSN: 1527-5299


  15 in total

1.  Oral Metolazone Versus Intravenous Chlorothiazide as an Adjunct to Loop Diuretics for Diuresis in Acute Decompensated Heart Failure With Reduced Ejection Fraction.

Authors:  Brian C Bohn; Rim M Hadgu; Hannah E Pope; Jerrica E Shuster
Journal:  Hosp Pharm       Date:  2018-08-30

Review 2.  Mineralocorticoid Receptor Antagonists for Treatment of Hypertension and Heart Failure.

Authors:  Domenic A Sica
Journal:  Methodist Debakey Cardiovasc J       Date:  2015 Oct-Dec

Review 3.  Diuretic use in renal disease.

Authors:  Domenic A Sica
Journal:  Nat Rev Nephrol       Date:  2011-12-20       Impact factor: 28.314

Review 4.  Loop diuretic resistance complicating acute heart failure.

Authors:  Zachary L Cox; Jeffrey M Testani
Journal:  Heart Fail Rev       Date:  2020-01       Impact factor: 4.214

5.  The Na+-excreting efficacy of indapamide in combination with furosemide in massive edema.

Authors:  Misa Tanaka; Emi Oida; Keiko Nomura; Fumiaki Nogaki; Atsushi Fukatsu; Kazuhide Uemura; Masatomo Yashiro; Takeshi Kimura; Eri Muso; Takahiko Ono
Journal:  Clin Exp Nephrol       Date:  2005-06       Impact factor: 2.801

6.  Diuretic treatment in high-risk acute decompensation of advanced chronic heart failure-bolus intermittent vs. continuous infusion of furosemide: a randomized controlled trial.

Authors:  Simone Frea; Stefano Pidello; Alessandra Volpe; Federico Giovanni Canavosio; Alessandro Galluzzo; Virginia Bovolo; Antonio Camarda; Pier Giorgio Golzio; Fabrizio D'Ascenzo; Serena Bergerone; Mauro Rinaldi; Fiorenzo Gaita
Journal:  Clin Res Cardiol       Date:  2019-06-29       Impact factor: 5.460

Review 7.  Medication management of chronic heart failure in older adults.

Authors:  Kannayiram Alagiakrishnan; Maciej Banach; Linda G Jones; Ali Ahmed; Wilbert S Aronow
Journal:  Drugs Aging       Date:  2013-10       Impact factor: 3.923

8.  Hypertension and end-organ disease in African Americans: case presentations.

Authors:  Domenic A Sica
Journal:  J Clin Hypertens (Greenwich)       Date:  2004-04       Impact factor: 3.738

Review 9.  The kidney and hypertension: causes and treatment.

Authors:  Domenic A Sica
Journal:  J Clin Hypertens (Greenwich)       Date:  2008-07       Impact factor: 3.738

Review 10.  Hypertension, renal disease, and drug considerations.

Authors:  Domenic A Sica
Journal:  J Clin Hypertens (Greenwich)       Date:  2004-10       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.